Advanced searches left 3/3
Search only database of 7.4 mil and more summaries

Levaquin Renal Dosing

Summarized by PlexPage
Last Updated: 24 October 2020

* If you want to update the article please login/register

General | Latest Info

The usual dose of LEVAQUIN Tablets is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1. These recommendations apply to patients with creatinine clearance of 50 mL / minute. For patients with creatinine clearance of less than 50 mL / min, adjustments to dosing regimen are require. Dosage of LEVAQUIN Tablets for inhalational anthrax and plague in pediatric patients who weigh 30 kg or greater is described below in Table 2. Levaquin Tablets cannot be administered to patients who weigh less than 30 kg because of limitations of available strength. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg. Administer LEVAQUIN with caution in patients with renal impairment. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced in these patients. In patients with renal impairment, adjustment of dosage regimen is necessary to avoid accumulation of levofloxacin due to decreased clearance. No adjustment is necessary for patients with creatinine clearance greater than or equal to 50 mL / minute. Table 3 shows how to adjust dose based on creatinine clearance. Levaquin Tablets should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable / buffer Tablets or pediatric powder for oral solution. If patients miss their dose, they should take it as soon as possible, anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose. Adequate hydration of patients receiving LEVAQUIN should be maintained to prevent formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones. In the event of acute overdosage, stomach should be empty. Patients should be observed and appropriate hydration maintain. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis. Levaquin exhibits low potential for acute toxicity. Mice, rats, dogs and monkeys exhibit following clinical signs after receiving a single high dose of LEVAQUIN: ataxia, ptosis, decreased locomotor activity, dyspnea, prostration, tremors, and convulsions. Doses in excess of 1500 mg / kg orally and 250 mg / kg IV produce significant mortality in rodents.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

INTRODUCTION

Medication dosing in obese individuals presents numerous pharmacokinetic challenges, including alterations in volume of distribution and enhanced Renal elimination. In general, dosing body weight and volume of distribution are dependent on the lipophilicity of the compound. Obese individuals have higher percentages of adipose tissue per body weight and higher overall amounts of adipose tissue. Thus, lipophilic agents are typically more widely distributed in obese people and tend TO require higher doses TO achieve therapeutic serum concentration. Obesity also accelerates drug elimination due to increased renal blood flow. Therefore, estimation of Creatinine Clearance based on commonly - used equations, such as Cockcroft - Gault, may lack accuracy as a means of predicting Renal function in obese population. Unfortunately, drug dosing in obese individuals is often difficult TO predict despite knowledge of physiochemical properties of giving medication, often making educated guesses as TO optimal dose incorrect. Acute or critical illness may also impact pharmacokinetics of medications. Specifically, volume of distribution, hepatic biotransformation, and elimination may be alter. Patients with Active inflammatory processes such as burn, trauma, or severe infection have reductions in plasma proteins such as albumin which allow for higher fraction of unbound Drug. In addition, so - call third - spacing of fluids also results in elevation in drug volume of distribution, as does fluid resuscitation. Hepatic biotransformation and Renal elimination may be elevated or decrease depending on the phase of critical illness and initiating factor. Levofloxacin is a fluoroquinolone antimicrobial agent used for treatment of community - and hospital - acquire infections. Currently, daily 750 - Mg Levofloxacin dose is approved by US Food and Drug ADMINISTRATION for Treatment Of Community - acquire and ventilator - associated Pneumonia, urinary tract infection, and complicated skin and skin structure infections. Levofloxacin pharmacokinetics are characterized by consistent absorption, distribution, and elimination in a wide range of populations, including healthy volunteers, elderly subjects and human immunodeficiency virus - infected individuals. Like many other fluoroquinolones, Levofloxacin is primarily renally eliminated and has extensive volume of distribution. Levofloxacin has exhibited altered pharmacokinetics in critical illness, specifically higher peak concentration, longer elimination half - life, and increased Overall Drug Exposure. Base on physiochemical and pharmacokinetic characteristics of Levofloxacin, disposition may also be altered in obese patients due TO changes in adipose tissue distribution and increased Renal Drug elimination. However, effects of obesity on Levofloxacin pharmacokinetics have not been describe. The present study proposes TO address the question of what are effects of severe obesity and of severe obesity and acute illness on Levofloxacin pharmacokinetics.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Warnings/Precautions:

Levaquin Tablets are synthetic antibacterial agents for oral ADMINISTRATION. Chemically, Levofloxacin, chiral fluorinated carboxyquinolone, is pure - enantiomer of the racemic drug substance ofloxacin. The chemical name is - 9fluoro - 2 3 - dihydro - 3methyl - 10 - 7oxo - 7H - pyrido - 1 4 - benzoxazine - 6carboxylic acid hemihydrate. The empirical formula is C 18 H 20 FN 3 O 4 H 2 O and the molecular weight is 370. 38. Levofloxacin is a light yellowish - white to yellow - white crystal or crystalline powder. Molecules exist as zwitterion at pH conditions in small intestine. Data demonstrates that pH is 0. 6 to 5. 8, solubility of Levofloxacin is essentially constant. Levofloxacin is considered soluble to freely soluble in this pH range, as defined by USP nomenclature. Above pH 5. 8, solubility increases rapidly to its maximum at pH 6. 7 and is considered freely soluble in this range. Above pH 6. 7, solubility decreases and reaches minimum value at pH of approximately 6. 9 Levofloxacin has the potential to form stable coordination compounds with many metal ions. This in vitro chelation potential has the following formation order: Al + 3 > Cu + 2 > Zn + 2 > Mg + 2 > Ca + 2. Levaquin Tablets are available as film - coat Tablets and contain the following inactive ingredients: 250 Mg: crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, synthetic red iron oxide and titanium dioxide. 500 Mg: crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, synthetic red and yellow iron oxides and titanium dioxide. 750 Mg: crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, titanium dioxide.


Levofloxacin side effects

Following Serious and otherwise important Adverse Drug Reactions are discussed in greater detail in other sections of labeling: disabling and Potentially Irreversible Serious Adverse Reactions Tendinitis and Tendon Rupture Peripheral Neuropathy Central Nervous System Effects Exacerbation of Myasthenia Gravis Other Serious and Sometimes Fatal Reactions Hypersensitivity Reactions Hepatotoxicity Clostridium difficile - associate Diarrhea Prolongation of QT Interval Musculoskeletal Disorders in Pediatric Patients Blood Glucose Disturbances Photosensitivity / Phototoxicity Development of Drug Resistant Bacteria crystalluria and cylindruria have been report with quinolones, including LEVAQUIN. Therefore, adequate hydration of patients receiving LEVAQUIN should be maintained to prevent formation of highly concentrated urine.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Estimating GFR and Creatinine Clearance

The study protocol was approved by the local ethics committee. Routine data was prospectively collected from patients hospitalized at Hopital Europeen Georges Pompidou between April 2016 and December 2017 for treatment of bone and joint infection. Patients with Renal Impairment requiring extra Renal replacement therapy were exclude. Blood samples were drawn after 2 or 3 Days of Treatment and consist of trough concentration followed by 3 Supplemental samples: 1 hour after following intake, 3 hours after intake, and just before the next intake. Demographic data were record: AGE, BW, gender, combined treatments, as well as biological data, if available on the same day as samples: proteinemia, albuminemia, serum glutamic pyruvic transaminase, serum glutamic oxaloacetatic transaminase, C - reactive protein, and glomerular Filtration Rate calculated by Modification Of Diet Renal Disease formula. When possible, Creatinine Clearance was calculated using the Cockcroft - Gault equation. Microbiological and clinical data were also record: causative bacteria, type of bone and joint infection, anatomical site, presence of surgical materials. All blood samples were centrifuge within 2 hours and plasma stored at 20 C until analysis, which was performed twice weekly. The sample assay consists of a validated LC - MS / MS method. Briefly, 50 L of desionized water and 50 L of internal standard were added to 50 L of plasma sample. Protein precipitation was performed by adding 75 L of trichloroacetic acid 5%. Samples were then vortex - mixed and centrifuge, and 50 L of supernatant were diluted with 200 L of ammonium acetate 0. 2 M before injection into the chromatographic system. Intra - and interday biases and imprecisions were inferior to 15% over the calibration range of method. Concentration - time data were analyzed by use of first - order conditional estimation with interaction method of non - linear mixed Effects modelling program NONMEM. Several structural pharmacokinetic models were investigate. Classical one - and two - compartment models with several error models were investigated as means of describing interpatient and residual variabilities. Interindividual variability was described by assuming that individual parameters arise from multivariate lognormal distribution with mean vector and variance - covariance matrix to be estimate. Interoccasion variability was also investigated as exponential models. Systematic testing for the influence of continuous covariates on pharmacokinetic parameters was done by use of a generalized model, according to the following equations: where TV is the typical value of apparent PK parameter for patients with mean covariate value, and COV is the corresponding influential factor. Gfr was the main covariate used to reflect Renal function. However, CLcr was also test. Categorical covariates were investigated according to the following equation: where COV was estimated for patients displaying covariate and was otherwise fixed to 1. When covariate was supposed to be related simultaneously to several PK parameters, same influential factor was estimated on all test parameters.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Adverse Effects

Levofloxacin is a broad - spectrum, third - generation fluoroquinolone antibiotic used to treat bacterial infections. Levofloxacin is a safe and effective medicine on the World Health Organization's essential medicines list. It was patented in 1987 and subsequently received FDA - approval in 1996 for medical use in the United States. Levofloxacin is FDA - approved for Treatment Of nosocomial Pneumonia, Community - acquire Pneumonia, acute Bacterial rhinosinusitis, acute Bacterial Exacerbation Of chronic bronchitis, prostatitis, acute pyelonephritis, urinary tract infection, skin or skin structure infections, prophylaxis and Treatment Of Plague due to Yersinia pestis, and TO reduce Incidence Of disease progression Of Inhalational Anthrax. Due to the increased risk of severe side effects, Levofloxacin is used only in patients with acute exacerbation of chronic bronchitis, acute Bacterial Sinusitis, and uncomplicated urinary tract infections, who do not have alternative treatment options. Ophthalmic Levofloxacin is also used in the treatment of Bacterial conjunctivitis. To decrease development of Drug - Resistant Bacteria, FDA has recommended using Levofloxacin only for strongly suspected bacterial infections. Also, Levofloxacin should not be used empirically in patients at risk of multidrug - Resistant Escherichia coli. Levaquin is indicated in Adult Patients for Treatment Of nosocomial Pneumonia due to methicillin - susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicate. Where Pseudomonas aeruginosa is document or presumptive pathogen, combination therapy with anti - pseudomonal - lactam is recommend. Levaquin is indicated in Adult Patients for Treatment Of Community - acquire Pneumonia due to methicillin - susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae. Mdrsp isolates are isolated resistant to two or more of the following antibacterials: penicillin, 2 generation cephalosporins, eg, cefuroxime, macrolides, tetracyclines and trimethoprim / sulfamethoxazole. Levaquin is indicated in Adult Patients for Treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. Levaquin is indicated in Adult Patients for treatment of complicated skin and skin structure infections due to methicillin - susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis. Levaquin is indicated in Adult Patients for treatment of uncomplicated skin and skin structure infections including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin - susceptible Staphylococcus aureus, or Streptococcus pyogenes. Levaquin is indicated in Adult Patients for Treatment of chronic Bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin - susceptible Staphylococcus epidermidis. Levaquin is indicated for Inhalational Anthrax TO reduce incidence or progression of disease following exposure TO aerosolized Bacillus anthracis in adults and pediatric patients, 6 months of age and older. Effectiveness of LEVAQUIN is based on plasma concentrations achieved in humans, surrogate endpoint reasonably likely TO predict clinical benefit. Levaquin has not been Test in humans for post - Exposure prevention of inhalation of Anthrax. The Safety of LEVAQUIN in adults for durations of therapy beyond 28 Days or in Pediatric Patients for durations of therapy beyond 14 Days has not been study. Prolonged LEVAQUIN therapy should only be used when benefits outweigh risk.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Pregnancy & Lactation

Urinary Tract infections are one of the most frequently occurring bacterial infections. In the United States alone, they account for over 7 million office visits and approximately 15% of Community - prescribed antibiotics. While the majority of these infections are uncomplicated, patients with complicated Urinary Tract infections are, by definition, at greater risk for adverse outcomes. Levofloxacin, widely - used fluoroquinolone, was approved in the US for treatment of cUTI and acute pyelonephritis in 1996 AND, more recently, in 2008, higher dose, short - course regimen was also approved for this indication. This review will examine clinical data available to evaluate the efficacy and safety of this antimicrobial for cUTI and AP. Generally, cUTI is considered to be an infection that occurs in the setting of any factor that predisposes to treatment failure or recurrence. However, no true consensus has been reached within the medical community as to what specifically defines cUTI. Traditionally, Urinary Tract infections in patient populations such as those with diabetes mellitus, pregnant females, and males have been considered to be complicated infections. Other descriptions of cUTI have also include patients who are elderly, have experienced recent instrumentation or antimicrobial treatment, or possess functional or anatomic abnormalities of genitourinary Tract. Ronald et al propose an alternate classification scheme, in which cUTI is characterized by presence of structural abnormalities, metabolic and / or hormonal abnormalities, impaired host responses, or infection with unusual Pathogen. Mandells Principles and Practice Of Infectious Diseases defines cUTIs as Urinary Tract infections in men, pregnant women, children, hospitalized patients, and patients with functional or structural abnormalities of the Urinary Tract. Ap is commonly described as an infection of the upper Urinary Tract that encompasses fever and flank pain and / or tenderness that are accompanied by dysuria and urinary urgency and frequency, although it is more accurately diagnosed based on the presence of these symptoms along with bacteriuria and acute Renal Infection. Ap was formerly treated largely on an inpatient basis, but recent trend towards outpatient management of this condition has been note. As seen in cUTI, most common pathogen causing AP is Escherichia coli. Fluoroquinolones have been extensively used in the management of genitourinary infections, especially acute uncomplicated cystitis. While fluoroquinolone resistance in uropathogens was once rare, resistance in E. Coli has emerged and continues to increase. Fluoroquinolone Resistance occurs through multiple mechanisms including chromosomal point mutations in genes encoding DNA gyrase and / or topoisomerase IV, mutations that cause decreased expression of outer membrane proteins, alterations in lipopolysaccharide component of cell envelope, and enhance fluoroquinolone efflux by efflux pumps such as AcrAB. Plasmid - borne Resistance has also recently been discover, and is caused by protection of DNA gyrase and topoisomerase IV by Qnr - like proteins, including QnrA. Surveillance of Urinary isolates collected between 1989 and 1997 found that fluoroquinolone Resistance in E. Coli was essentially nonexistent during this time frame.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summarized are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo
jooble logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.